Clinical Trials · NCT04844918
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 267
- Start date
- May 2021
- Locations
- 18 sites, Japan
- Primary endpoint
- Mean Percent Change in Body Weight